Research Library

Corruption is a complex social, political and institutional problem that is difficult to define. This brief describes the challenges involved in defining, understanding and measuring corruption and evaluates the case study of Mexico, where corruption has increased in recent years, to illustrate these complexities.

The authors examine adherence to treatment guidelines for colon cancer among elderly patients in Texas.

Higher costs for complex cancer surgery may be an indicator for worse, rather than better, quality of care, according to new research by the Baker Institute and the University of Texas MDAnderson Cancer Center. The study suggests that lower patient costs achieved by high-volume surgeons can be explained by the lower occurrence of “processes of care”— many of which are taken to avoid or treat complications that can occur during surgery, such as placing arterial lines or providing epidural anesthesia.

With the Texas Legislature now considering several bills that would decrease penalties for marijuana possession and legalize the use of medical marijuana to treat a variety of conditions, authors William Martin and Katharine A. Neill present updated findings in this new issue brief that support the case for reforming marijuana policy in Texas.

As his term progresses, President Trump will be faced with a large number of policy challenges, some of them requiring immediate science & technology expertise. In this Science Magazine article, the authors urge the president to consider the Office of Science & Technology Policy, the science advisor and the presidential S&T councils as vital resources that should be used early in the term to drive his policy agenda.

The author analyzes the major claims and implications of the Surgeon General's report "Facing Addiction in America," and proposes additional drug policy considerations for addressing substance use disorders.

High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.